[<sup>68</sup>Ga]Ga-DOTATATE-avid tumor volume, uptake and inflammation-based index correlate with survival in neuroendocrine tumor patients treated with [<sup>177</sup>Lu]Lu-DOTATATE PRRT.

Elin Pauwels(KU Leuven), Christophe M. Deroose(KU Leuven), Sander Jentjens(KU Leuven), Christophe Dooms(Chinese Academy of Medical Sciences & Peking Union Medical College), Karolien Goffin(KU Leuven), Kristof Baete(KU Leuven), Jeroen Dekervel(Universitair Ziekenhuis Leuven), Koen Van Laere(Universitair Ziekenhuis Leuven), Chris Verslype(Universitair Ziekenhuis Leuven), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven)
PubMed
January 1, 2022
Cited by 11

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k